Skip to the page

Data / New clinical trials / Company sponsors / Guangdong Raynovent Biotech Co., Ltd

Guangdong Raynovent Biotech Co., Ltd trials: 36 (2026)

Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

ClinicalTrials.gov lists 36 trials with Guangdong Raynovent Biotech Co., Ltd as lead sponsor, 6 of them recruiting or not yet recruiting.

The full list. Clinical trials led by Guangdong Raynovent Biotech Co., Ltd: 36 rows for $5, every trial on ClinicalTrials.gov.

$10 of credit on sign-up, no card. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/company/guangdong-raynovent-biotech-co-ltd, and every list with its row count and price is at https://specstream.ai/data/lists.json.

The request: Every clinical trial Guangdong Raynovent Biotech Co., Ltd leads on ClinicalTrials.gov, with phase, status, conditions and sites, and each new one.

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

Trials
36
Recruiting or not yet
6
Read on
November 19, 2026

Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

First postedNCT IDTitleSponsorPhaseStatusConditionsEnrollmentSource
September 18, 2026NCT07827027Evaluation of the Bioequivalence of RAY1225 Injection in Healthy ParticipantsGuangdong Raynovent Biotech Co., LtdPhase 1Not yet recruitingBasic Science68clinicaltrials.gov
March 10, 2026NCT07460284A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese ParticipantsGuangdong Raynovent Biotech Co., LtdPhase 1Not yet recruitingBasic Science8clinicaltrials.gov
January 23, 2026NCT07362030Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and DigoxinGuangdong Raynovent Biotech Co., LtdPhase 1Active not recruitingObesity32clinicaltrials.gov
November 17, 2025NCT07229820Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza AGuangdong Raynovent Biotech Co., LtdPhase 3CompletedInfluenza A157clinicaltrials.gov
November 17, 2025NCT07229807Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza AGuangdong Raynovent Biotech Co., LtdPhase 3CompletedInfluenza a120clinicaltrials.gov
August 24, 2025NCT07139548A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesGuangdong Raynovent Biotech Co., LtdPhase 3Not yet recruitingT2DM600clinicaltrials.gov
August 24, 2025NCT07139535A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneGuangdong Raynovent Biotech Co., LtdPhase 3Not yet recruitingT2DM350clinicaltrials.gov
March 25, 2025NCT06893016Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightGuangdong Raynovent Biotech Co., LtdPhase 3RecruitingObesity640clinicaltrials.gov
October 24, 2024NCT06656026Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza AGuangdong Raynovent Biotech Co., LtdPhase 2CompletedInfluenza a72clinicaltrials.gov
September 26, 2024NCT06613763A Study of RAY1225 in Participants With Impaired Kidney FunctionGuangdong Raynovent Biotech Co., LtdPhase 1CompletedKidney Impairment32clinicaltrials.gov
August 29, 2024NCT06577428A Study of RAY1225 at Different Injection Sites in Participants With Different Body SizesGuangdong Raynovent Biotech Co., LtdPhase 1CompletedHealthy48clinicaltrials.gov
August 29, 2024NCT06577415A Study of RAY1225 in Participants With Impaired Liver FunctionGuangdong Raynovent Biotech Co., LtdPhase 1UnknownHepatic Impairment24clinicaltrials.gov
April 12, 2024NCT06362460Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in ChinaGuangdong Raynovent Biotech Co., LtdPhase 1CompletedPharmacokinetics6clinicaltrials.gov
February 12, 2024NCT06254274A Study of RAY1225 in Participants With Type 2 DiabetesGuangdong Raynovent Biotech Co., LtdPhase 2CompletedT2DM (Type 2 Diabetes Mellitus)210clinicaltrials.gov
February 12, 2024NCT06254261A Study of RAY1225 in Participants With ObesityGuangdong Raynovent Biotech Co., LtdPhase 2RecruitingObesity270clinicaltrials.gov
February 8, 2024NCT06248567Pharmacokinetics of ZSP1273 in Participants With Severe Kidney DiseaseGuangdong Raynovent Biotech Co., LtdPhase 1CompletedKidney Impairment16clinicaltrials.gov
December 13, 2023NCT06169085Pharmacokinetics of Leritrelvir(Ray1216) in Elder ParticipantsGuangdong Raynovent Biotech Co., LtdPhase 1CompletedElder32clinicaltrials.gov
December 11, 2023NCT06164431Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273Guangdong Raynovent Biotech Co., LtdPhase 1CompletedBioequivalence32clinicaltrials.gov
December 7, 2023NCT06161259Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic ImpairmentGuangdong Raynovent Biotech Co., LtdPhase 1CompletedHepatic Impairment24clinicaltrials.gov
December 7, 2023NCT06160622Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney DiseaseGuangdong Raynovent Biotech Co., LtdPhase 1CompletedKidney Impairment16clinicaltrials.gov
December 5, 2023NCT06157450Pharmacokinetics of ZSP1273 in Elder ParticipantsGuangdong Raynovent Biotech Co., LtdPhase 1CompletedElder32clinicaltrials.gov
September 11, 2023NCT06031454Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and RifampinGuangdong Raynovent Biotech Co., LtdPhase 1CompletedDrug Drug Interaction56clinicaltrials.gov
July 20, 2023NCT05954624Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and ProbenecidGuangdong Raynovent Biotech Co., LtdPhase 1CompletedDrug Drug Interaction49clinicaltrials.gov
July 12, 2023NCT05942365A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and MidazolamGuangdong Raynovent Biotech Co., LtdPhase 1CompletedDrug Drug Interaction, Warfarin, Midazolam28clinicaltrials.gov
May 24, 2023NCT05873426Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in ChinaGuangdong Raynovent Biotech Co., LtdPhase 1CompletedPharmacokinetics6clinicaltrials.gov

By phase

PhaseTrials
Phase 122
Phase 1/22
Phase 25
Phase 37

By status

StatusTrials
Completed27
Not yet recruiting4
Recruiting2
Active not recruiting2
Unknown1

Conditions

Condition groupTrials
Obesity4
Non-alcoholic Fatty Liver Disease3
Renal Insufficiency3
Idiopathic Pulmonary Fibrosis1
COVID-191
Diabetes Mellitus, Type 21

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown. Free to quote with credit and a link. Copying in bulk needs a data licence. Spot a wrong value? Write to [email protected] with the link to this page.

$10 of credit on sign-up, no card.

Get this list free

Business lists in the United States

More public records